Upregulation of TRIB2 by Wnt/ β-catenin activation in BRAFV600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib
ConclusionOur study showed that the upregulation of TRIB2 by the Wnt/ β-catenin activation confers resistance to vemurafenib in PTC withBRAFV600 mutation. These findings support the potential use of TRIB2 as a therapeutic target for resistant PTC.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Epithelial Cancer | Study | Thyroid | Thyroid Cancer